- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Oliver Dorigo on Identified Biomarkers in Gynecologic Malignancies
We have a number of biomarkers that we have shown are associated with a better response to certain new therapies, said Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
We have a number of biomarkers that we have shown are associated with a better response to certain new therapies, said Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.
Transcript
What biomarkers have you identified to determine prognosis and treatment outcomes in gynecologic malignancies?
We have a number of biomarkers that we have shown are associated with a better response to certain new therapies. PARP inhibitors, for example, work the best in those patients that have either germline mutations of BRCA1 and BRCA2 or those mutations only in the tumor tissue. It’s particularly true in ovarian cancer, where we have the most experience.
We also know that certain ovarian cancers have a certain degree of defects and repair mechanisms that the cell uses to repair DNA damage. If these mechanisms are dysfunctional, then patients, again, are more likely to respond to PARP inhibitors. We call this a so-called homologous recombination deficiency score, which is a measure or a biomarker that predicts the response to PARP inhibitors, at least to some extent.
In immunotherapy, biomarkers relate mostly to what we call microsatellite instability, which does increase the probability of a patient responding to immune-checkpoint inhibition.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
